pdac
Entity, reached from Hormuz.
- Evidence
- 41 documents · 17 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 8 Apr 2026, last seen 9 Oct 2026
- Measured
- 12% of mentions say something specific about it; the rest only name it
- As of
- 10 Oct 2026
Where this comes from
- bioRxiv Cancer Biology · 2026-10-06 · HMGA2 Expression in Pancreatic Ductal Adenocarcinoma Controls Tumor Microenvironment and Immunosuppression via IL1α (opens the source in a new tab)
- Cancer Res · 2026-10-02 · Targeting Distinct Cell Cycle Nodes Overcomes RAS Inhibitor Resistance. (opens the source in a new tab)
- Inside Precision Medicine · 2026-10-01 · Oncolytic Virus May Boost First-in-Line Chemotherapy for Metastatic PDAC (opens the source in a new tab)
- Expert Opin Biol Ther · 2026-09-28 · Harnessing novel agents to target KRAS-driven pathways in pancreatic cancer. (opens the source in a new tab)
- bioRxiv Cancer Biology · 2026-09-25 · Context-specific genetic interaction mapping reveals combinatorial KRAS/FGFR dependence in pancreatic cancer (opens the source in a new tab)
- Semin Oncol · 2026-09-23 · Oncolytic viruses in gastrointestinal malignancies: Clinical progress, translational challenges, and future directions. (opens the source in a new tab)
- Oncologist · 2026-09-23 · Current Landscape of RAS-Targeted Therapy for Pancreatic Cancer. (opens the source in a new tab)
- Proc Natl Acad Sci U S A · 2026-09-22 · IRE1α-XBP1s signaling links lipid homeostasis to hypoxic maladaptation and KRAS inhibitor responses in pancreatic ductal adenocarcinoma. (opens the source in a new tab)
- MedComm (2020) · 2026-09-20 · Tripterine Liposome Exerts Antitumor and Immunomodulatory Effects in Pancreatic Ductal Adenocarcinoma. (opens the source in a new tab)
- Cancer Cell · 2026-09-16 · Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer. (opens the source in a new tab)
1 more on file, counted in the evidence above.
What is claimed about it
Situations it is named in
Who it moves with
- co-mentioned with kras (24 documents)seen together
- co-mentioned with pancreatic cancer (22 documents)seen together
- co-mentioned with immunotherapy (12 documents)seen together
- co-mentioned with colorectal cancer (10 documents)seen together
- co-mentioned with g12d (10 documents)seen together
- co-mentioned with fda (9 documents)seen together